secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-06-01T23:59:59+00:00
Accession:  0001437749-23-016319
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Atossa appoints Greg Weaver as CFO, succeeding Kyle Guse effective June 1, 2023
-------------------------------------------------------------------------------

- Greg Weaver appointed EVP and CFO effective June 1, 2023, succeeding Kyle Guse who ceased as of May 26, 2023.
- Weaver receives $450K base salary, 45% target bonus, $125K sign-on, and 2.6M stock options vesting over 4 years.
- Weaver previously served as CFO of BioIntelliSense, Atai Life Sciences, and Eloxx Pharmaceuticals; also a director since 2013.
- Guse will receive severance benefits per his employment agreement upon termination without cause.
- Weaver's severance includes 6 months salary/benefits, or 12 months with equity acceleration upon change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923016319/0001437749-23-016319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923016319/atos20230526_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-016319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer